First National Trust Co boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,897 shares of the medical research company’s stock after purchasing an additional 1,239 shares during the period. First National Trust Co’s holdings in Thermo Fisher Scientific were worth $930,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of Nova Scotia Trust Co. acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $106,000. Ropes Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares in the last quarter. Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $138,000. Acrospire Investment Management LLC grew its holdings in Thermo Fisher Scientific by 66.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after purchasing an additional 400 shares in the last quarter. Finally, Glassman Wealth Services grew its holdings in Thermo Fisher Scientific by 23.1% during the 2nd quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 195 shares in the last quarter. 86.25% of the stock is owned by institutional investors and hedge funds.
Thermo Fisher Scientific Inc. (NYSE TMO) opened at $212.41 on Friday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific Inc. has a 52-week low of $140.00 and a 52-week high of $213.06. The stock has a market cap of $84,730.00, a PE ratio of 36.06, a PEG ratio of 1.69 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. During the same period last year, the firm posted $2.03 EPS. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. research analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Monday, January 15th. Stockholders of record on Friday, December 15th were given a $0.15 dividend. The ex-dividend date was Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is currently 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.49% of the company’s stock.
TMO has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Leerink Swann raised their price objective on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective for the company. Finally, BTIG Research began coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They set a “buy” rating and a $230.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $212.21.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/19/thermo-fisher-scientific-inc-tmo-position-raised-by-first-national-trust-co.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.